In last trading session, Altimmune Inc (NASDAQ:ALT) saw 1.72 million shares changing hands with its beta currently measuring 1.14. Company’s recent per share price level of $4.97 trading at $0.12 or 2.47% at ring of the bell on the day assigns it a market valuation of $382.76M. That closing price of ALT’s stock is at a discount of -124.55% from its 52-week high price of $11.16 and is indicating a premium of 28.57% from its 52-week low price of $3.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.11 million shares which gives us an average trading volume of 2.50 million if we extend that period to 3-months.

For Altimmune Inc (ALT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.20. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.34 in the current quarter.

Altimmune Inc (NASDAQ:ALT) trade information

Upright in the green during last session for gaining 2.47%, in the last five days ALT remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $4.97 price level, adding 4.79% to its value on the day. Altimmune Inc’s shares saw a change of -31.07% in year-to-date performance and have moved 9.71% in past 5-day. Altimmune Inc (NASDAQ:ALT) showed a performance of -17.85% in past 30-days. Number of shares sold short was 21.82 million shares which calculate 7.14 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 25 to the stock, which implies a rise of 80.12% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -141.45% in reaching the projected high whereas dropping to the targeted low would mean a loss of -141.45% for stock’s current value.

Altimmune Inc (ALT) estimates and forecasts

This year revenue growth is estimated to rise 111,022.20% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 560 for the same. And 9 analysts are in estimates of company making revenue of 560 in the next quarter. Company posted 5k and 5k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 3.48% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -6.99% while estimates for its earnings growth in next 5 years are of 0.77%.

Altimmune Inc (NASDAQ:ALT)’s Major holders

Insiders are in possession of 0.80% of company’s total shares while institution are holding 53.82 percent of that, with stock having share float percentage of 54.25%. Investors also watch the number of corporate investors in a company very closely, which is 53.82% institutions for Altimmune Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ALT for having 5.32 million shares of worth $35.39 million. And as of 2024-06-30, it was holding 7.5025 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.91 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.9181 of outstanding shares, having a total worth of $32.63 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.24 shares of worth $11.12 million or 2.90% of the total outstanding shares. The later fund manager was in possession of 1.91 shares on Mar 31, 2025 , making its stake of worth around $9.51 million in the company or a holder of 2.49% of company’s stock.